Patent · US Active

Polypeptides for inhibiting complement activation

US11591378B2 · kind B2 · utility

0Cited by

2References

19Claims

0Family size

Assignee

ELEVA GMBH · DE

Inventors

Stefan Michelfelder · Denzlingen, DE
Karsten Häffner · Freiburg (Elbe), DE

Key dates

Filing date	Mar 20, 2020
Grant date	Feb 28, 2023
Priority date	—
Expiry date	Mar 20, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/74
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a polypeptide comprising a C3 convertase effector domain, a C5 convertase effector domain and optionally a terminal complex inhibitory effector domain which is resistant to deregulation by physiologic FHR-Proteins and has a dimerization motif, and to its therapeutic use.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.